Literature DB >> 10982790

Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma.

K Pekkari1, R Gurunath, E S Arner, A Holmgren.   

Abstract

Human thioredoxin (Trx) catalyzes intracellular disulfide reductions but has also co-cytokine activity with interleukins after leaderless secretion. A recombinant truncated form of thioredoxin with the 80 N-terminal residues (Trx80) was purified to homogeneity. We discovered that Trx80 by itself is a potent mitogenic cytokine stimulating growth of resting human peripheral blood mononuclear cells. No effect was seen by Trx, but Trx80 at 50-100 nm induced cell proliferation of human peripheral blood mononuclear cells in serum-free synthetic medium, measured as [(3)H]thymidine incorporation after 72 h, with a maximum effect being comparable with that of 5 units/ml of interleukin-2. Trx80 lacked redox activity, but CD spectra suggested a secondary structure similar to Trx. Reduced Trx80 had an M(r) of 25,000, indicating that it is a dimer in solution. We also developed two different sandwich enzyme-linked immunosorbent assays that distinguish between full-length Trx and Trx80 and determined plasma levels of Trx and Trx80 in blood donors. The levels of Trx80 varied from 2 to 175 ng/ml; in comparison levels of Trx varied from 16 to 55 ng/ml without correlation to Trx80. In conclusion, the naturally occurring Trx80 is a novel mitogenic cytokine for normal resting human blood mononuclear cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10982790     DOI: 10.1074/jbc.M001012200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis.

Authors:  H Nakamura; L A Herzenberg; J Bai; S Araya; N Kondo; Y Nishinaka; L A Herzenberg; J Yodoi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

Review 2.  The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker?

Authors:  Alexey A Tinkov; Geir Bjørklund; Anatoly V Skalny; Arne Holmgren; Margarita G Skalnaya; Salvatore Chirumbolo; Jan Aaseth
Journal:  Cell Mol Life Sci       Date:  2018-01-11       Impact factor: 9.261

3.  Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure.

Authors:  Gustav Nilsonne; Eric Olm; Adam Szulkin; Filip Mundt; Agnes Stein; Branka Kocic; Anna-Klara Rundlöf; Aristi P Fernandes; Mikael Björnstedt; Katalin Dobra
Journal:  J Exp Clin Cancer Res       Date:  2009-06-29

Review 4.  Thioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling.

Authors:  Eva-Maria Hanschmann; José Rodrigo Godoy; Carsten Berndt; Christoph Hudemann; Christopher Horst Lillig
Journal:  Antioxid Redox Signal       Date:  2013-03-28       Impact factor: 8.401

5.  Thioredoxin-80 protects against amyloid-beta pathology through autophagic-lysosomal pathway regulation.

Authors:  Gorka Gerenu; Torbjörn Persson; Julen Goikolea; Javier Calvo-Garrido; Raúl Loera-Valencia; Philipp Pottmeier; Cesar Santiago; Helen Poska; Jenny Presto; Angel Cedazo-Minguez
Journal:  Mol Psychiatry       Date:  2019-09-13       Impact factor: 15.992

6.  Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer's disease brain.

Authors:  Francisco Gil-Bea; Susanne Akterin; Torbjörn Persson; Laura Mateos; Anna Sandebring; Javier Avila-Cariño; Angel Gutierrez-Rodriguez; Erik Sundström; Arne Holmgren; Bengt Winblad; Angel Cedazo-Minguez
Journal:  EMBO Mol Med       Date:  2012-08-30       Impact factor: 12.137

7.  Thioredoxin 80-activated-monocytes (TAMs) inhibit the replication of intracellular pathogens.

Authors:  Ximena Cortes-Bratti; Eugénie Bassères; Fabiola Herrera-Rodriguez; Silvia Botero-Kleiven; Giuseppe Coppotelli; Jens B Andersen; Maria G Masucci; Arne Holmgren; Esteban Chaves-Olarte; Teresa Frisan; Javier Avila-Cariño
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

8.  Rod-derived Cone Viability Factor-2 is a novel bifunctional-thioredoxin-like protein with therapeutic potential.

Authors:  Frédéric Chalmel; Thierry Léveillard; Céline Jaillard; Aurélie Lardenois; Naomi Berdugo; Emmanuelle Morel; Patrice Koehl; George Lambrou; Arne Holmgren; José A Sahel; Olivier Poch
Journal:  BMC Mol Biol       Date:  2007-08-31       Impact factor: 2.946

9.  Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems.

Authors:  Simona Casagrande; Valentina Bonetto; Maddalena Fratelli; Elisabetta Gianazza; Ivano Eberini; Tania Massignan; Mario Salmona; Geng Chang; Arne Holmgren; Pietro Ghezzi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

Review 10.  Cell stress proteins in atherothrombosis.

Authors:  Julio Madrigal-Matute; Roxana Martinez-Pinna; Carlos Ernesto Fernandez-Garcia; Priscila Ramos-Mozo; Elena Burillo; Jesus Egido; Luis Miguel Blanco-Colio; Jose Luis Martin-Ventura
Journal:  Oxid Med Cell Longev       Date:  2012-06-25       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.